EE200200510A - POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks - Google Patents

POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks

Info

Publication number: EE200200510A
Authority: EE; Estonia
Prior art keywords: factor viii; amino acid; acid sequence; porcine factor; modified porcine
Prior art date: 2000-03-10

Application number

EEP200200510A

Other languages

English (en)

Inventor

S. Lollar John

Original Assignee

Emory University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-10

Filing date

2001-02-16

Publication date

2004-02-16

2001-02-16 Application filed by Emory University filed Critical Emory University

2004-02-16 Publication of EE200200510A publication Critical patent/EE200200510A/et

2008-10-15 Publication of EE05075B1 publication Critical patent/EE05075B1/et

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Glass Compositions (AREA)
Fish Paste Products (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)

EEP200200510A 2000-03-10 2001-02-16 POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseks EE05075B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/523,656 US6458563B1 (en)	1996-06-26	2000-03-10	Modified factor VIII
PCT/US2001/005076 WO2001068109A1 (en)	2000-03-10	2001-02-16	Modified factor viii

Publications (2)

Publication Number	Publication Date
EE200200510A true EE200200510A (et)	2004-02-16
EE05075B1 EE05075B1 (et)	2008-10-15

Family

ID=24085870

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200200510A EE05075B1 (et)	2000-03-10	2001-02-16	POL1212 aminohappejrjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII-tegur, sellel p?hinev ravimkompositsioon ning meetod sea modifitseeritud VIII-teguri aminohappejrjestust omava valgu valmistamiseks

Country Status (35)

Country	Link
US (3)	US6458563B1 (et)
EP (1)	EP1280540B1 (et)
JP (1)	JP4044337B2 (et)
KR (1)	KR100485525B1 (et)
CN (1)	CN1191360C (et)
AT (1)	ATE391512T1 (et)
AU (2)	AU3841601A (et)
BE (1)	BE2016C024I2 (et)
BR (2)	BRPI0109131B8 (et)
CA (1)	CA2400295C (et)
CY (2)	CY1108179T1 (et)
CZ (1)	CZ298250B6 (et)
DE (1)	DE60133541T2 (et)
DK (1)	DK1280540T3 (et)
EE (1)	EE05075B1 (et)
ES (1)	ES2304379T3 (et)
FR (1)	FR16C0016I2 (et)
HU (2)	HU227804B1 (et)
IL (2)	IL151371A0 (et)
LT (1)	LTC1280540I2 (et)
LU (1)	LU93049I2 (et)
ME (1)	ME00601B (et)
MX (1)	MXPA02008798A (et)
NL (1)	NL300808I2 (et)
NO (2)	NO331935B1 (et)
NZ (1)	NZ520799A (et)
PL (1)	PL202936B1 (et)
PT (1)	PT1280540E (et)
RS (1)	RS50364B (et)
RU (1)	RU2285724C2 (et)
SI (1)	SI1280540T1 (et)
SK (1)	SK286205B6 (et)
UA (1)	UA75064C2 (et)
WO (1)	WO2001068109A1 (et)
ZA (1)	ZA200206810B (et)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7560107B2 (en)	1996-06-26	2009-07-14	Emory University	Modified factor VIII
CA2434097A1 (en) *	2001-01-12	2002-08-08	The American National Red Cross	Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
JP4634036B2 (ja) *	2001-10-05	2011-02-16	エクスプレッションセラピューティクス，エルエルシー	高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
WO2003047507A2 (en) *	2001-11-30	2003-06-12	Emory University	Factor viii c2 domain variants
GB0207092D0 (en)	2002-03-26	2002-05-08	Sod Conseils Rech Applic	Stable pharmaceutical composition containing factor VIII
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
WO2005017149A1 (en) *	2003-06-03	2005-02-24	Cell Genesys, Inc.	Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) *	2003-06-03	2009-02-03	Cell Genesys, Inc.	Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
DE602004007924T2 (de) *	2003-06-26	2008-04-10	Merck Patent Gmbh	Thrombopoietinproteine mit verbesserten eigenschaften
US20050059023A1 (en) *	2003-09-16	2005-03-17	Cantor Thomas L.	Methods and kits for monitoring resistance to therapeutic agents
US7211559B2 (en) *	2003-10-31	2007-05-01	University Of Maryland, Baltimore	Factor VIII compositions and methods
DE602004026474D1 (de) *	2003-12-03	2010-05-20	Univ Rochester	Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2005107776A1 (en)	2004-05-03	2005-11-17	Emory University	METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
WO2005123928A1 (en) *	2004-06-08	2005-12-29	Battelle Memorial Institute	Production of human coagulation factor viii from plant cells and whole plants
ES2633916T3 (es) *	2004-11-12	2017-09-26	Bayer Healthcare Llc	Modificación de FVIII dirigida al sitio
US20100256062A1 (en) *	2004-12-06	2010-10-07	Howard Tommy E	Allelic Variants of Human Factor VIII
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007065691A2 (en)	2005-12-07	2007-06-14	Technische Universität München	Small peptidic and peptido-mimetic affinity ligands for factor viii and factor viii-like proteins
EP1816201A1 (en)	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
JP2009533364A (ja) *	2006-04-11	2009-09-17	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	治療用ポリペプチドのインビボでの回収を増大させる方法
US7939632B2 (en) *	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (en) *	2006-12-22	2008-06-25	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
JP5448839B2 (ja)	2006-12-22	2014-03-19	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	インビボで長い半減期を有する修飾された凝固因子
FR2913020B1 (fr) *	2007-02-23	2012-11-23	Biomethodes	Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP1988101A1 (en) *	2007-05-04	2008-11-05	Novo Nordisk A/S	Improvement of factor VIII polypeptide titers in cell cultures
MX2010004813A (es) *	2007-11-01	2010-10-04	Univ Rochester	Factor viii recombinante que tiene estabilidad incrementada.
EP2149603A1 (en)	2008-07-28	2010-02-03	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EA020843B1 (ru)	2009-02-03	2015-02-27	Амуникс Оперейтинг Инк.	Удлиненные рекомбинантные полипептиды и содержащие их композиции
TWI626057B (zh)	2009-06-09	2018-06-11	普龍製藥有限責任公司	血紅素組成物
US20120263701A1 (en)	2009-08-24	2012-10-18	Volker Schellenberger	Coagulation factor vii compositions and methods of making and using same
CA2780763A1 (en) *	2009-11-13	2011-05-19	Puget Sound Blood Center	Factor viii b cell epitope variants having reduced immunogenicity
DK2506868T3 (da)	2009-12-06	2018-01-29	Bioverativ Therapeutics Inc	Kimæriske og hybride faktor viii-fc-polypeptider og fremgangsmåder til anvendelse deraf
EP2524054A2 (en) *	2010-01-14	2012-11-21	Haplomics, Inc.	Predicting and reducing alloimmunogenicity of protein therapeutics
DK2591006T3 (da)	2010-07-09	2019-07-29	Bioverativ Therapeutics Inc	Processerbare enkeltkædede molekyler og polypeptider fremstillet ved anvendelse deraf
US9611310B2 (en)	2010-07-09	2017-04-04	Bioverativ Therapeutics Inc.	Systems for factor VIII processing and methods thereof
MY165089A (en)	2010-11-05	2018-02-28	Baxalta Inc	A new variant of antihemophilic factor viii having increased specific activity
KR20140036144A (ko) *	2011-01-05	2014-03-25	익스프레션 테라퍼틱스 엘엘씨	고수율 현탁세포주, 시스템 및 그 제조방법
HUE043894T2 (hu)	2011-06-10	2019-09-30	Bioverativ Therapeutics Inc	Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
PL3513804T3 (pl)	2011-07-08	2022-07-11	Bioverativ Therapeutics Inc.	Chimeryczne i hybrydowe polipeptydy czynnika VIII i sposoby ich stosowania
EP2737311B1 (en)	2011-07-25	2020-12-02	Bioverativ Therapeutics Inc.	Assays to monitor bleeding disorders
CN102277379B (zh) *	2011-08-18	2013-07-24	中国科学院遗传与发育生物学研究所	表达凝血因子viii的表达载体及其应用
PL2802668T3 (pl)	2012-01-12	2019-03-29	Bioverativ Therapeutics Inc.	Sposoby zmniejszania immunogenności wobec czynnika krzepnięcia viii u pacjentów poddawanych leczeniu czynnikiem krzepnięcia viii
CN104271150A (zh)	2012-01-12	2015-01-07	比奥根艾迪克Ma公司	嵌合因子viii多肽及其用途
MX369862B (es)	2012-02-15	2019-11-25	Bioverativ Therapeutics Inc	Composiciones del factor viii y metodos para hacerlas y usarlas.
NZ628014A (en)	2012-02-15	2016-09-30	Biogen Ma Inc	Recombinant factor viii proteins
EP2666782A1 (en) *	2012-05-22	2013-11-27	Imnate Sarl	Coagulation factor VIII with reduced immunogenicity.
CA2875247A1 (en)	2012-06-08	2013-12-12	Biogen Idec Ma Inc.	Chimeric clotting factors
AU2013270682A1 (en)	2012-06-08	2014-12-11	Biogen Ma Inc.	Procoagulant compounds
US10023628B2 (en)	2012-07-06	2018-07-17	Bioverativ Therapeutics Inc.	Cell line expressing single chain factor VIII polypeptides and uses thereof
RS59876B1 (sr)	2012-07-11	2020-03-31	Bioverativ Therapeutics Inc	Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
EP3970738A1 (en)	2012-07-25	2022-03-23	Bioverativ Therapeutics Inc.	Blood factor monitoring assay and uses thereof
EP2908847B1 (en)	2012-10-18	2022-03-30	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
EP2914293A4 (en)	2012-10-30	2016-04-20	Biogen Ma Inc	METHOD OF USE OF FVIII POLYPEPTIDE
WO2014089541A2 (en)	2012-12-07	2014-06-12	Haplomics, Inc.	Factor viii mutation repair and tolerance induction
ES2959747T3 (es)	2013-02-15	2024-02-28	Bioverativ Therapeutics Inc	Gen del factor VIII optimizado
UY35463A (es)	2013-03-15	2014-10-31	Biogen Idec Inc	Formulaciones de polipéptido fc-factor ix.
PL3666283T3 (pl)	2013-03-15	2022-10-03	Bioverativ Therapeutics Inc.	Formulacje polipeptydu czynnika viii
KR102714760B1 (ko)	2013-06-28	2024-10-11	바이오버라티브 테라퓨틱스 인크.	Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
WO2015021423A2 (en)	2013-08-08	2015-02-12	Biogen Idec Ma Inc.	Purification of chimeric fviii molecules
EP3033097B1 (en)	2013-08-14	2021-03-10	Bioverativ Therapeutics Inc.	Factor viii-xten fusions and uses thereof
MX2016005333A (es)	2013-10-22	2017-02-15	Dbv Tech	Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos.
EP3065769A4 (en)	2013-11-08	2017-05-31	Biogen MA Inc.	Procoagulant fusion compound
US10325687B2 (en)	2013-12-06	2019-06-18	Bioverativ Therapeutics Inc.	Population pharmacokinetics tools and uses thereof
EP2881463A1 (en)	2013-12-09	2015-06-10	DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH	Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
PT4176894T (pt)	2014-01-10	2024-05-21	Bioverativ Therapeutics Inc	Proteínas quiméricas de fator viii e utilizações destas
WO2015120056A1 (en)	2014-02-04	2015-08-13	Biogen Ma Inc.	Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3107561A4 (en) *	2014-02-19	2017-12-20	Bloodworks	Factor viii b cell epitope variants having reduced immunogenicity
EP3114138B1 (en)	2014-03-05	2021-11-17	Pfizer Inc.	Improved muteins of clotting factor viii
WO2016004113A1 (en)	2014-06-30	2016-01-07	Biogen Ma Inc.	Optimized factor ix gene
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
CA2994547A1 (en)	2015-08-03	2017-02-09	Bioverativ Therapeutics Inc.	Factor ix fusion proteins and methods of making and using same
PE20231949A1 (es) *	2015-10-30	2023-12-05	Spark Therapeutics Inc	VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
US10189888B2 (en)	2015-11-13	2019-01-29	Baxalta Incorporated	Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
SG11201804064WA (en)	2015-11-13	2018-06-28	Baxalta Inc	Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
EP3411478B1 (en)	2016-02-01	2022-06-08	Bioverativ Therapeutics Inc.	Optimized factor viii genes
WO2017222337A1 (ko)	2016-06-24	2017-12-28	재단법인 목암생명과학연구소	Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US12257288B2 (en)	2016-12-02	2025-03-25	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of treating hemophilic arthropathy using chimeric clotting factors
WO2018208973A1 (en) *	2017-05-09	2018-11-15	Emory University	Clotting factor variants and their use
MY203184A (en)	2017-08-09	2024-06-13	Bioverativ Therapeutics Inc	Nucleic acid molecules and uses thereof
EP3746136A1 (en)	2018-02-01	2020-12-09	Bioverativ Therapeutics Inc.	Use of lentiviral vectors expressing factor viii
UY38160A (es)	2018-04-04	2019-11-29	Sigilon Therapeutics Inc	Partículas implantables y métodos relacionados
SG11202010767SA (en)	2018-05-18	2020-11-27	Bioverativ Therapeutics Inc	Methods of treating hemophilia a
CA3106590A1 (en)	2018-07-16	2020-01-23	Baxalta Incorporated	Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
MX2021001599A (es)	2018-08-09	2021-07-02	Bioverativ Therapeutics Inc	Moleculas de acido nucleico y sus usos para la terapia genica no viral.
UY38389A (es)	2018-09-27	2020-04-30	Sigilon Therapeutics Inc	Dispositivos implantables para terapia celular y métodos relacionados
TWI851647B (zh)	2019-01-16	2024-08-11	日商武田藥品工業股份有限公司	用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
WO2020257462A1 (en)	2019-06-19	2020-12-24	Bioverativ Therapeutics Inc.	Recombinant factor viii-fc for treating hemophilia and low bone mineral density
US20200405883A1 (en)	2019-06-20	2020-12-31	Baxalta Incorporated	Method of treatment with viral-based gene therapy
US12403164B2 (en)	2019-09-30	2025-09-02	Bioverativ Therapeutics Inc.	Lentiviral vector formulations
EP4073106A2 (en)	2019-12-12	2022-10-19	Takeda Pharmaceutical Company Limited	Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
JP2023537565A (ja)	2020-06-24	2023-09-04	バイオベラティブセラピューティクスインコーポレイテッド	タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
TW202246505A (zh) *	2021-03-05	2022-12-01	俄羅斯聯邦商亞那拜恩有限公司	編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途
US11906532B2 (en)	2021-03-31	2024-02-20	Haemonetics Corporation	Hemostasis measurement device quality control formulations
WO2022264040A1 (en)	2021-06-14	2022-12-22	Takeda Pharmaceutical Company Limited	Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202323274A (zh)	2021-08-23	2023-06-16	美商百歐維拉提夫治療公司	優化因子viii基因
IL311725A (en)	2021-09-30	2024-05-01	Bioverativ Therapeutics Inc	Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
WO2024081309A1 (en)	2022-10-11	2024-04-18	Sigilon Therapeutics, Inc.	Engineered cells and implantable elements for treatment of disease
TW202517669A (zh)	2023-07-05	2025-05-01	日商武田藥品工業股份有限公司	用於Ａ型血友病之基因療法的編碼表現增加之重組ＦＶｌｌｌ變異體的病毒載體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
EP0182448A3 (en)	1984-08-24	1987-10-28	Genetics Institute, Inc.	Production of factor viii and related products
DE3683980D1 (de) *	1985-04-12	1992-04-02	Genetics Inst	Neue prokoagulierungsproteine.
JPH0387173A (ja)	1987-09-10	1991-04-11	Teijin Ltd	ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
DK162233C (da)	1989-11-09	1992-03-16	Novo Nordisk As	Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
EP0502976B1 (en) *	1989-12-01	1996-07-03	Pharming B.V.	Production of recombinant polypeptides by bovine species and transgenic methods
US5663060A (en)	1992-04-07	1997-09-02	Emory University	Hybrid human/animal factor VIII
US6180371B1 (en) *	1996-06-26	2001-01-30	Emory University	Modified factor VIII
US5364771A (en)	1992-04-07	1994-11-15	Emory University	Hybrid human/porcine factor VIII
US5563045A (en)	1992-11-13	1996-10-08	Genetics Institute, Inc.	Chimeric procoagulant proteins
WO1997003191A1 (en)	1995-07-11	1997-01-30	Chiron Corporation	Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains
AU6455896A (en)	1995-07-11	1997-02-10	Chiron Corporation	Novel factor viii:c polypeptide analogs with altered metal-binding properties
EP1319016A4 (en) *	2000-09-19	2006-05-10	Univ Emory	MODIFIED FACTOR VIII
WO2003047507A2 (en) *	2001-11-30	2003-06-12	Emory University	Factor viii c2 domain variants
US7105745B2 (en) *	2002-12-31	2006-09-12	Thomas & Betts International, Inc.	Water resistant electrical floor box cover assembly

2000
- 2000-03-10 US US09/523,656 patent/US6458563B1/en not_active Expired - Lifetime
2001
- 2001-02-16 ES ES01910853T patent/ES2304379T3/es not_active Expired - Lifetime
- 2001-02-16 MX MXPA02008798A patent/MXPA02008798A/es active IP Right Grant
- 2001-02-16 PL PL359672A patent/PL202936B1/pl unknown
- 2001-02-16 CZ CZ20023346A patent/CZ298250B6/cs unknown
- 2001-02-16 ME MEP-2009-82A patent/ME00601B/me unknown
- 2001-02-16 DE DE60133541T patent/DE60133541T2/de not_active Expired - Lifetime
- 2001-02-16 WO PCT/US2001/005076 patent/WO2001068109A1/en not_active Ceased
- 2001-02-16 IL IL15137101A patent/IL151371A0/xx unknown
- 2001-02-16 UA UA2002097145A patent/UA75064C2/uk unknown
- 2001-02-16 SK SK1439-2002A patent/SK286205B6/sk not_active IP Right Cessation
- 2001-02-16 BR BRPI0109131A patent/BRPI0109131B8/pt not_active IP Right Cessation
- 2001-02-16 HU HU0300586A patent/HU227804B1/hu active Protection Beyond IP Right Term
- 2001-02-16 AU AU3841601A patent/AU3841601A/xx active Pending
- 2001-02-16 BR BR122013026957A patent/BR122013026957A8/pt not_active Application Discontinuation
- 2001-02-16 EP EP01910853A patent/EP1280540B1/en not_active Expired - Lifetime
- 2001-02-16 SI SI200130823T patent/SI1280540T1/sl unknown
- 2001-02-16 AT AT01910853T patent/ATE391512T1/de active
- 2001-02-16 EE EEP200200510A patent/EE05075B1/et active Protection Beyond IP Right Term
- 2001-02-16 RS YUP-680/02A patent/RS50364B/sr unknown
- 2001-02-16 PT PT01910853T patent/PT1280540E/pt unknown
- 2001-02-16 DK DK01910853T patent/DK1280540T3/da active
- 2001-02-16 AU AU2001238416A patent/AU2001238416B2/en active Active
- 2001-02-16 RU RU2002124123/13A patent/RU2285724C2/ru active
- 2001-02-16 NZ NZ520799A patent/NZ520799A/en not_active IP Right Cessation
- 2001-02-16 KR KR10-2002-7011843A patent/KR100485525B1/ko not_active Expired - Lifetime
- 2001-02-16 CA CA2400295A patent/CA2400295C/en not_active Expired - Lifetime
- 2001-02-16 CN CNB018063179A patent/CN1191360C/zh not_active Expired - Lifetime
- 2001-02-16 JP JP2001566673A patent/JP4044337B2/ja not_active Expired - Lifetime
2002
- 2002-06-28 US US10/187,319 patent/US7012132B2/en not_active Expired - Fee Related
- 2002-08-21 IL IL151371A patent/IL151371A/en active IP Right Grant
- 2002-08-26 ZA ZA200206810A patent/ZA200206810B/en unknown
- 2002-09-09 NO NO20024296A patent/NO331935B1/no not_active IP Right Cessation
2004
- 2004-09-10 US US10/938,414 patent/US7122634B2/en not_active Expired - Fee Related
2008
- 2008-07-07 CY CY20081100709T patent/CY1108179T1/el unknown
2016
- 2016-04-27 LU LU93049C patent/LU93049I2/xx unknown
- 2016-04-29 FR FR16C0016C patent/FR16C0016I2/fr active Active
- 2016-05-02 BE BE2016C024C patent/BE2016C024I2/fr unknown
- 2016-05-06 LT LTPA2016014C patent/LTC1280540I2/lt unknown
- 2016-05-09 NL NL300808C patent/NL300808I2/nl unknown
- 2016-05-09 HU HUS1600020C patent/HUS1600020I1/hu unknown
- 2016-05-10 NO NO2016007C patent/NO2016007I1/no unknown
- 2016-05-10 CY CY2016011C patent/CY2016011I1/el unknown

Also Published As

Publication number	Publication date
KR20020081426A (ko)	2002-10-26
NL300808I2 (nl)	2020-12-21
PT1280540E (pt)	2008-06-09
CZ298250B6 (cs)	2007-08-01
NL300808I1 (et)	2016-05-18
SK14392002A3 (sk)	2003-06-03
HK1051004A1 (en)	2003-07-18
BRPI0109131B1 (pt)	2020-08-25
MEP8209A (en)	2011-12-20
ATE391512T1 (de)	2008-04-15
NO20024296L (no)	2002-11-08
CN1191360C (zh)	2005-03-02
LU93049I2 (fr)	2016-06-27
SI1280540T1 (sl)	2008-08-31
AU2001238416B2 (en)	2004-09-02
ZA200206810B (en)	2003-11-26
DE60133541D1 (de)	2008-05-21
PL359672A1 (en)	2004-09-06
CN1416348A (zh)	2003-05-07
WO2001068109A1 (en)	2001-09-20
BR122013026957A2 (et)	2004-12-07
RS50364B (sr)	2009-11-10
US7122634B2 (en)	2006-10-17
MXPA02008798A (es)	2003-04-25
SK286205B6 (sk)	2008-05-06
RU2002124123A (ru)	2004-03-27
US6458563B1 (en)	2002-10-01
CA2400295A1 (en)	2001-09-20
KR100485525B1 (ko)	2005-04-28
UA75064C2 (en)	2006-03-15
EP1280540A1 (en)	2003-02-05
FR16C0016I1 (et)	2016-04-29
FR16C0016I2 (fr)	2018-11-02
NO2016007I2 (no)	2016-05-10
CZ20023346A3 (cs)	2003-01-15
BRPI0109131B8 (pt)	2021-07-06
ME00601B (me)	2011-12-20
CY2016011I2 (el)	2016-10-05
EP1280540A4 (en)	2004-11-03
AU3841601A (en)	2001-09-24
US20030068785A1 (en)	2003-04-10
HUS1600020I1 (hu)	2016-06-28
NO331935B1 (no)	2012-05-07
BR122013026957A8 (pt)	2017-02-21
CA2400295C (en)	2012-01-10
JP2003526358A (ja)	2003-09-09
CY1108179T1 (el)	2014-02-12
BE2016C024I2 (et)	2020-01-30
ES2304379T3 (es)	2008-10-16
DE60133541T2 (de)	2009-05-07
NO2016007I1 (no)	2016-05-10
HUP0300586A2 (hu)	2003-06-28
IL151371A (en)	2010-12-30
BR0109131A (pt)	2004-12-07
YU68002A (sh)	2005-11-28
LTC1280540I2 (lt)	2020-05-25
NZ520799A (en)	2004-06-25
CY2016011I1 (el)	2016-10-05
US20050079584A1 (en)	2005-04-14
JP4044337B2 (ja)	2008-02-06
PL202936B1 (pl)	2009-08-31
US7012132B2 (en)	2006-03-14
DK1280540T3 (da)	2008-07-14
EE05075B1 (et)	2008-10-15
HU227804B1 (en)	2012-03-28
EP1280540B1 (en)	2008-04-09
IL151371A0 (en)	2003-04-10
HUP0300586A3 (en)	2006-11-28
NO20024296D0 (no)	2002-09-09
RU2285724C2 (ru)	2006-10-20

Publication	Publication Date	Title
EE200200510A (et)	2004-02-16	POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks
PT1200105E (pt)	2005-06-30	Factor viii modificado
BR9814276A (pt)	2000-10-03	Antìgenos de superfìcie
DE60032486D1 (de)	2007-02-01	Prion protein peptide und deren verwendung
ATE485371T1 (de)	2010-11-15	Varianten des menschlichen koagulationsfaktors vii
BRPI0411321A (pt)	2006-07-18	vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus
DE69632546D1 (de)	2004-06-24	Ob proteinderivate mit verlängerter halbwertzeit
NO20063026L (no)	2006-08-28	Antistoffer
EA200700973A1 (ru)	2007-12-28	Слитый белок, содержащий домен bh3 белка «вh3-только»
DE69935078D1 (de)	2007-03-22	Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen
ATE251886T1 (de)	2003-11-15	Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE342977T1 (de)	2006-11-15	Nukleinsäure, die für polypeptide kodieren die eine mutt-domäne enthalten
DE60024977D1 (de)	2006-01-26	Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DK0811068T3 (da)	2003-03-10	Humane DNase I varianter
ATE512981T1 (de)	2011-07-15	Identifizierung von ses-3 (spr-5) aus c. elegans sowie dessen verwendungen
ATE427955T1 (de)	2009-04-15	Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen

Legal Events

Date	Code	Title	Description
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2016-06-15	AA1Y	Spc filed	Free format text: PRODUCT NAME: SUSOKTOKOG ALFA;REG NO/DATE: EU/1/15/1035 13.11.2015 Spc suppl protection certif: C20160010 Filing date: 20160509
2016-06-15	HE1A	Change of address
2016-07-15	FG1Y	Spc granted	Free format text: PRODUCT NAME: SUSOKTOKOG ALFA;REG NO/DATE: EU/1/15/1035 13.11.2015 Spc suppl protection certif: C20160010 00183 Filing date: 20160509 Extension date: 20260216